Biomarkers, surrogate markers for disease activity including C-reactive protein (CRP) and fecal calprotectin (FC), have therefore become increasingly utilized noninvasive measures of IBD activity as an intermediate step in the treat-to-target approach. This evidence concerns the gene CRP and irritable bowel syndrome.